It will provide first-hand data for "Class B and Class B management". China's first large-scale real world study of anti COVID-19 drugs launches clinical | COVID-19 | Class B

Release time:Apr 13, 2024 21:24 PM

Recently, China's first large-scale real world research on anti COVID-19 drugs on the market was launched in Beijing. This study, involving more than 100 large hospitals and primary medical institutions in 30 provinces, autonomous regions and cities across the country, will include real data of nearly 40000 COVID-19 patients. The study will reflect the clinical program, follow-up mechanism, medical expenses and other aspects of COVID-19 treatment in China, and further explore the efficacy, safety and pharmacoeconomic value of anti COVID-19 drugs, so as to provide first-hand data for the normalization management of COVID-19 "Class B and Class B".

The so-called real-world research refers to the collection and analysis of health-related data on predetermined clinical problems in a non-human designed environment, to study the effectiveness and safety of drugs in the real world. The "Research on the Therapeutic Effect of Anti COVID-19 Drugs on COVID-19 in Chinese Medical and Health Institutions" was initiated by the China Community Health Association, and led by Professor Jiang Rongmeng of Beijing Ditan Hospital affiliated to Capital Medical University. The study focused on the real scene of COVID-19's diagnosis and treatment. Doctors timely entered data and regularly followed up COVID-19 infected people during the diagnosis and treatment process, and realized the whole course management of patients through the digital platform, accumulating more extensive evidence for the clinical application of COVID-19 drugs; Meanwhile, by analyzing the overall medical expenses of patients, we can answer which treatment model has more clinical and pharmacoeconomic advantages.

Professor Jiang Rongmeng said that there are more and more COVID-19 small molecule drugs and their clinical accessibility is getting better, but there is still a lack of large sample real world research, as well as large sample pharmacoeconomic evaluation, head to head comparative research of antiviral drugs, etc. This study will help to explore the advantages and disadvantages of anti COVID-19 drugs, and also promote medical institutions to detect and treat patients with COVID-19 at an early stage, so as to reduce the conversion of disease to severe disease.

Professor Jiang Rongmeng teaches research methods to doctors involved in real-world research.

The COVID-19 small molecule oral drugs approved for listing in China are two imported ones and four domestic ones. From the perspective of the target of action, it can be divided into two categories: one type acts on the 3CL target, mainly including Pfizer's Paxlovid, Xiansheng Pharmaceutical's Xiannuoxin, and Zhongsheng's Leruiling; Another type is RdRp inhibitors, mainly including Azvudine in real organisms, Monolavir in Mercadon, and Mindavir in Junshi Biotechnology.


It will provide first-hand data for "Class B and Class B management". China's first large-scale real world study of anti COVID-19 drugs launches clinical | COVID-19 | Class B

Paxlovid targets the 3CL target and uses a combination of "nematevir+ritonavir" drugs. Among domestic drugs, Xiannuoxin also adopts a combination therapy of Xiannuotevir and Litonavir targeting this target. The 3CL target is highly conserved, not easily affected by viral mutations, and has high safety with no reproductive or genetic toxicity. The combination of ritonavir for antiviral treatment has a long history. Whether it is pexlovid's nematevir or sinoxin's sinovir, with the assistance of ritonavir, both drugs can delay their metabolic breakdown in the body and improve their antiviral efficacy.

Wang Chen, an academician of the CAE Member and an expert in respiratory medicine and critical care medicine, said: 3CL drugs are the mainstream among anti COVID-19 drugs. 3CL drugs combined with ritonavir therapy have been adjusted from "emergency use authorization" to official approval of the US FDA, proving the effectiveness and safety of this treatment. He believes that the domestically produced 3CL drug Xiannuoxin has outstanding characteristics in effectiveness and safety, with scientific basis and solid clinical evidence.

At present, anti COVID-19 drugs listed in China are listed according to the special drug approval procedure, with conditions attached after emergency review. Its main channel for obtaining drugs is through hospital prescriptions. Experts in the department of infectious diseases said that accelerating the post marketing research of COVID-19 drugs and making domestic COVID-19 drugs fully available without "conditionality" will help improve the accessibility of domestic affordable COVID-19 drugs for oral use, and people are expected to obtain drugs more conveniently through Internet hospitals, social pharmacies and other channels.

It is reported that on online platforms such as Taobao, JD.com, and Meituan, offline medical institutions with prescriptions for Kaixian Nuoxin, Paxlovid, and Mindewe can be booked; Search for "COVID-19 Special Medicine" or "Convenient Medicine Map", and you can get the medicine according to the guide. On the WeChat platform, search the "Xiannuoxin Drug Interaction" applet, and you can also obtain the popular science knowledge of COVID-19 disease, understand the interaction of multiple drugs, and query the nearby medical institutions with drugs.

Shanghai International Sister City Youth "Play" Summer Camp Experience Traditional Culture, Make Pankou, Learn Paper Cuttings, Make Dumplings International | Youth | Make Dumplings
Shanghai International Sister City Youth "Play" Summer Camp Experience Traditional Culture, Make Pankou, Learn Paper Cuttings, Make Dumplings International | Youth | Make Dumplings

Making coils, learning Paper Cuttings, making dumplings, walking into the home of summer camp volunteers and feeling the life of Shanghai people... On the 20th, the 2023 Shanghai International Sister City Youth Summer Camp officially opened in Shanghai Shidong Experimental School. 73 campers from 13 cities in 12 countries gathered in Shanghai to open the annual international sister city youth exchange event with their peers in Shanghai. The young partners together carried out activities such as learning excellent traditional Chinese culture courses such as Chinese and traditional Chinese painting, intangible cultural heritage, Chinese clothing, disco, Paper Cuttings, seal cutting, calligraphy, pottery, tea art, Yanzhi, dragon dance, youth forum exchanges in sister cities, investigation of urban cultural landscape, visits to universities and venues, city orientation challenges, and local family life experiences, etc., to bloom their youth. In addition to a rich and colorful summer camp physical activity experience, campers and volunteers

Undergraduate voluntary application starts today! These important reminders and suggestions must be read, @ College Entrance Examination Stage | Undergraduate | Volunteer
Undergraduate voluntary application starts today! These important reminders and suggestions must be read, @ College Entrance Examination Stage | Undergraduate | Volunteer

@All college entrance examination candidates, according to the schedule of the college entrance examination, will fill in their undergraduate preferences for all batches except for the comprehensive evaluation batch from 8:00 a.m. to 8:00 p.m. daily from July 1st to 2nd, and from 8:00 a.m. to 12:00 a.m. on July 3rd. The specific contents of this voluntary application include zero voluntary batch, advance batch, art and sports class A batch, local rural special plan batch, special type enrollment, and ordinary batch. The filling method is as follows: Fresh high school graduates in this city will be arranged uniformly by the high school where they are enrolled; Non local fresh high school graduates will be arranged uniformly by the district recruitment office where they apply. It is important to remind candidates that during the voluntary application period from July 1st to 3rd, as the admission of the comprehensive evaluation batch has not yet been completed, candidates who have filled out the comprehensive evaluation batch of voluntary applications still need to carefully fill out other batches of undergraduate voluntary applications

Investment+Services Drive Anti Cancer Drugs into Clinical Practice | Entrepreneurial Stories in Incubators, Second Entrepreneurial Biology for CEOs of Listed Companies | Incubators | Clinical | Incubators
Investment+Services Drive Anti Cancer Drugs into Clinical Practice | Entrepreneurial Stories in Incubators, Second Entrepreneurial Biology for CEOs of Listed Companies | Incubators | Clinical | Incubators

Recently, with the approval of the National Medical Products Administration, the Class 1 innovative drug CC312 developed by Huihe Biotechnology has initiated phase I clinical trials for the treatment of recurrent/refractory CD19 positive B-cell malignant hematological tumors. This is the first domestically and the third globally approved triple specific antibody drug based on CD28 co stimulatory signals to enter clinical practice. When it comes to the development history of this new triple antibody drug, Dr. Zhu Huaxing, the founder of Huihe Biotechnology, still remembers vividly: "Before 2019, there was no triple antibody drug approved for clinical use globally, and some investors couldn't understand CC312. During a critical period of company development, Nokai Xinkang Fund invested 30 million yuan to help us complete Series A financing." Nokai Xinkang is a venture capital fund initiated by Xinze Entrepreneurship Incubator. This incubation company, which has been deeply cultivated in Zhangjiang Science City for many years

"Zidong Taichu" Full Modal Large Model Released, Precisely Positioned 3D Scene, Listening to "Moonlight Song" and Talking about Beethoven Images | Applications | Beethoven
"Zidong Taichu" Full Modal Large Model Released, Precisely Positioned 3D Scene, Listening to "Moonlight Song" and Talking about Beethoven Images | Applications | Beethoven

Not only can you hear Beethoven talk freely in "Moonlight", but you can also achieve precise positioning in three-dimensional scenes, and complete scene analysis through the combination of images and sound. On June 16, at the AI Framework Ecological Summit, the Institute of Automation of the Chinese Academy of Sciences officially released the full mode large model of "Zidong Taichu". This model is the 2.0 version upgraded from the 1.0 version of the 100 billion parameter multimodal model "Zidong Taichu". On the basis of voice, image and text three modes, it adds video, sensor signal, 3D point cloud and other modal data, breaks through the key technologies such as multimodal correlation for cognitive enhancement, and has full modal understanding, generation and correlation capabilities. At the meeting, Xu Bo, the director of the Institute of Automation, presented for the first time in real time the "Zidong Taichu" full modal cognitive model in music understanding

Perseverance is a life experience. Lingling Middle School has weak muscles. Candidates complete the college entrance examination: no matter what difficulties they experience. High school | school | college entrance examination
Perseverance is a life experience. Lingling Middle School has weak muscles. Candidates complete the college entrance examination: no matter what difficulties they experience. High school | school | college entrance examination

"The college entrance examination is an experience in our lives. Looking back on the preparation for the entire senior year of high school, we cannot help but marvel at the preciousness of time. No matter what difficulties we have gone through, I believe that as long as we persist, it will become my lifelong wealth. Today, after completing the morning foreign language listening and speaking test of the college entrance examination, Xiao Song, a senior student of Lingling High School, came out of the examination center of East China University of Science and Technology Affiliated Middle School. The senior year graduate sitting in a wheelchair said," Although academic and life are not small tests for me, I have faced many difficulties in adversity and have never given up on my dream of taking the college entrance examination. "Xiao Song suffered from congenital muscular dystrophy since childhood and entered Lingling High School in high school." Later, the school provided him with classrooms on low floors and close to the toilet, making it easier for him to enter and exit, allowing him to face his academic life with more confidence. At school, I met many kind and enthusiastic people